Business Description
BioXcel Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US09075P1057
Description
Financial Strength
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.64 | |||||
Equity-to-Asset | -0.77 | |||||
Debt-to-Equity | -1.79 | |||||
Debt-to-EBITDA | -0.61 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -17.51 | |||||
Beneish M-Score | 2.24 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -14.5 | |||||
3-Year EPS without NRI Growth Rate | -16.6 | |||||
3-Year FCF Growth Rate | -20.1 | |||||
Future 3-5Y Total Revenue Growth Rate | 191.72 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 47.44 | |||||
9-Day RSI | 47.96 | |||||
14-Day RSI | 47.27 | |||||
6-1 Month Momentum % | -10.64 | |||||
12-1 Month Momentum % | -87.51 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.65 | |||||
Quick Ratio | 2.57 | |||||
Cash Ratio | 2.39 | |||||
Days Inventory | 571.44 | |||||
Days Sales Outstanding | 93.52 | |||||
Days Payable | 3096.91 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7 | |||||
Shareholder Yield % | -73.81 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 8.62 | |||||
Operating Margin % | -12146.45 | |||||
Net Margin % | -12974.86 | |||||
FCF Margin % | -11259.66 | |||||
ROE % | -2323.67 | |||||
ROA % | -127.86 | |||||
ROIC % | -2730.34 | |||||
ROC (Joel Greenblatt) % | -9373.37 | |||||
ROCE % | -154.28 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 56.04 | |||||
EV-to-EBIT | -0.69 | |||||
EV-to-Forward-EBIT | -1.26 | |||||
EV-to-EBITDA | -0.7 | |||||
EV-to-Forward-EBITDA | -1.33 | |||||
EV-to-Revenue | 83.41 | |||||
EV-to-Forward-Revenue | 45.54 | |||||
EV-to-FCF | -0.76 | |||||
Earnings Yield (Greenblatt) % | -144.91 | |||||
FCF Yield % | -196.41 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
BioXcel Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 1.279 | ||
EPS (TTM) (€) | -5.708 | ||
Beta | 1.4 | ||
Volatility % | 124.97 | ||
14-Day RSI | 47.27 | ||
14-Day ATR (€) | 0.115286 | ||
20-Day SMA (€) | 2.49505 | ||
12-1 Month Momentum % | -87.51 | ||
52-Week Range (€) | 1.83 - 27.6 | ||
Shares Outstanding (Mil) | 30.58 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
BioXcel Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
BioXcel Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
BioXcel Therapeutics Inc Frequently Asked Questions
What is BioXcel Therapeutics Inc(FRA:BX2)'s stock price today?
When is next earnings date of BioXcel Therapeutics Inc(FRA:BX2)?
Does BioXcel Therapeutics Inc(FRA:BX2) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |